Earnings OutlookThe current consensus estimates for 2025 look 'very aggressive', raising concerns about the company's ability to meet these expectations.
Financial PerformanceThe company fell short of the Street sales target for Nutrition, and international core lab performance was impacted by VBP, particularly in China.
Litigation RisksA jury in St. Louis ordered ABT to pay $495M in the company's first necrotizing-enterocolitis case, with the amount much more than Reckitt due to St Louis jurisdiction allowing for punitive damages.